Latest News

Ocrelizumab approved by Medsafe

December 22, 2017 | Advocacy, Treatments

Media Release – 22 December 2017 The Multiple Sclerosis Society of New Zealand (MSNZ) is pleased that Medsafe[1] has approved the registration of ocrelizumab (Ocrevus®) for both Relapsing (RMS) and Primary Progressive (PPMS) multiple sclerosis (MS) in New Zealand.   […]


MSNZs position on Stem Cell Transplantation

November 9, 2017 | Advocacy, Life with MS, Research, Treatments

Following TVNZs Sunday programme last night on people with multiple sclerosis seeking stem cell transplantation overseas for their MS, the Multiple Sclerosis Society of New Zealand (MSNZ) confirms its support for the use of this treatment within a clinical trial […]


Multiple Sclerosis: Looking towards the future of MS treatments

September 18, 2017 | Advocacy, Education, Event, Treatments, Uncategorised

Multiple sclerosis is a chronic neurological condition of the central nervous system affecting 4000 New Zealanders and with 134 new people being diagnosed each year. While the exact cause and cure of MS is currently unknown, there are treatments available, […]


Drastic under-resourcing of DHB neurology services means NZ is falling well short of internationally-approved standards of care for people with multiple sclerosis

August 22, 2017 | Advocacy, Life with MS

Media release 6 July 2017   The Multiple Sclerosis Society of New Zealand (MSNZ) is extremely concerned about the negative impact of the current shortage of neurologists and multiple sclerosis (MS) nurses in DHBs around New Zealand. “The shortage of […]


Actively Advocating

August 22, 2017 | Advocacy, Life with MS

  In 2016 MSNZ conducted the Multiple Sclerosis Care Survey which highlighted several issues affecting access to services received by people with MS across the county, particularly an inequity in access. MSNZ reviewed the feedback alongside listening to our member […]